People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juvenescence Ltd | — | Biotechnology | Series C | $121.9M | $324.3M | 2020 |
Susan Bergin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Susan Bergin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Mellon | 1 | 10 |
| Gregory Bailey | 1 | 8 |
| Declan Doogan | 1 | 6 |
| Denham Eke | 1 | 4 |
| David Roblin | 1 | 3 |
| Colin Watts | 1 | 2 |
| David Ellam | 1 | 1 |
| Jean-Christophe Renondin | 1 | 1 |
| Alex Pickett | 1 | 1 |
| Karim Hakimzadeh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.